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Even if NOTCH1 is commonly mutated in Chronic Lymphocytic Leukemia (CLL), its 
functional impact in the disease remains unclear. Using CRISPR/Cas9-generated cell 
models, we show that NOTCH1 regulates growth and homing of CLL cells by dictating 
expression levels of the tumor suppressor gene DUSP22. Specifically, NOTCH1 affects 
the methylation of DUSP22 promoter by modulating a nuclear complex, which tunes the 
activity of DNA methyltransferase 3A (DNMT3A). These effects are enhanced by PEST-
domain mutations, which stabilize the molecule and prolong signaling. CLL patients with 
a NOTCH1-mutated clone showed low levels of DUSP22 and active chemotaxis to CCL19. 
Lastly, in xenograft models, NOTCH1-mutated cells displayed a unique homing behavior, 
localizing preferentially to the spleen and brain. These findings connect NOTCH1, 
DUSP22, and CCL19-driven chemotaxis within a single functional network, suggesting 
that modulation of the homing process may provide a relevant contribution to the 




Exome sequencing identified previously unrecognized, recurrently mutated genes in 
CLL. NOTCH1 mutations are found in ≈10% of CLL patients at diagnosis, with the 
prevalence increasing to ≈20% in relapsed patients, and to ≈30% in the subset that 
undergoes transformation to Richter’s syndrome (RS) (1-4). Several studies report 
strong associations between NOTCH1 mutations and unmutated immunoglobulin V 
genes (IgHV), stereotyped B cell receptors typical of subset #8, trisomy 12, and an 
increased risk of RS (5-10). Furthermore, patients with NOTCH1 mutations have a 
shorter time to first treatment and reduced overall survival, independent of other 
prognostic indicators (7, 11). The impact of NOTCH1 mutations as drivers of clonal 
evolution in CLL remains unclear. However, NOTCH1 mutations occur early in the 
disease process, since they are found in patients with monoclonal B cell lymphocytosis 
(12, 13) as well as in patients with RS (14). 
In a significant proportion of cases, NOTCH1 mutations in CLL are represented by a 2bp 
frameshift deletion mutation at position 7541-7542 (∆CT_7541-7542), leading to the 
formation of a premature STOP codon, resulting in a shorter protein. The protein lacks 
the ubiquitination site and is thus predicted to remain transcriptionally active in the 
nucleus for a longer time.  
In a prior comparison of NOTCH1 expression and signaling in CLL patients carrying WT or 
∆CT_7541-7542 mutation, we showed that mutated patients are characterized by 
increased expression of NOTCH1 targets, such as HES1 and DTX1, which are prototypes 
of the canonical and non-canonical pathway. We also showed that, regardless of 
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mutational status, NOTCH1 signaling must be activated through interactions with the 
surface ligands (15). From a functional perspective, NOTCH1 mutations render CLL cells 
more resistant to spontaneous or drug-induced apoptosis (16, 17). 
Binding to ligands belonging to the Jagged or DLL families starts multiple proteolytic 
cleavages of the NOTCH1 protein, the last of which is operated by the γ-secretase 
enzyme, causing nuclear translocation of the NOTCH1-IntraCellular-Domain (NICD) (18). 
Once in the nucleus, the NICD forms a transcription complex with the DNA binding 
protein RBPJk and other co-activators (19). The presence of the more stable, mutant, 
form of NICD is predicted to alter the nuclear balance between RBPJk, the NICD itself, 
and histone deacetylase 1 (HDAC1) which also binds to RBPJk (20).  
Here, by using a cellular model lacking NOTCH1 or expressing it in a WT or mutant form, 
we show that NOTCH1 modulates the expression of molecules involved in signaling and 
movement. We highlight a novel nuclear circuit, which connects the NICD to the activity 
of the DNMT3A, through RBPJk and HDAC1. This circuit modulates methylation and 
subsequent expression of the tumor suppressor DUSP22, which in turn negatively 




NOTCH1-deficient Mec-1 cells are generated using CRISPR technology and 
reconstituted using lentiviruses encoding WT or  mutant NICD 
To address the role of NOTCH1 in CLL homeostasis, we exploited the CLL-derived Mec-1 
cell line, which constitutively expresses wild-type (WT) NOTCH1 at high levels (Fig. 1A-
B). By using CRISPR/Cas9 technology targeted to exon 2 of the gene, we generated a 
Mec-1 variant lacking NOTCH1 (Mec-1/KO) (fig. S1A). Transfected cells were then sorted 
for GFP and cloned by limiting dilution. The clones were screened by Sanger sequencing 
to check for missense mutations in the area targeted by the guide (fig. S1B). Lack of 
NOTCH1 expression was confirmed by qRT-PCR and western blot (WB) (Fig. 1A-B). Three 
different clones constitutively lacking NOTCH1 were used for further studies.  
To elucidate the role of the mutations in the NOTCH1 PEST domain, which are typical of 
CLL patients, Mec-1/KO cells were infected with GFP-tagged lentiviruses encoding either  
WT or  mutant NICD, designated KONICD and KONICD-M, respectively. The mutant NICD was 
generated by site-specific mutagenesis to obtain the  ∆CT_7541-7542 mutation. 
Expression of WT or mutant NICD was confirmed by WB, which showed multiple bands 
corresponding to the NICD (Fig. 1A). As expected, the presence of the mutation resulted 
in bands of lower molecular weight, compatible with the appearance of a premature 
STOP codon. By immunoprecipitation (IP) with an anti-NOTCH1 antibody, we confirmed 
that these molecular species react with an anti-NOTCH1 antibody (fig. S2). qRT-PCR 
showed that NOTCH1 expression in the infected cells was comparable to that of Mec-
1/WT (Fig. 1B). 
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Expression of NOTCH1-dependent genes was then studied by RT-PCR in at least three 
different KO, KONICD, and KONICD-M clones, the latter two selected for expressing 
comparable levels of NOTCH1. Loss of NOTCH1 expression was followed by a drop in the 
expression of HES1 and DTX1 (Fig. 1C-D), which was restored by reconstitution of a 
transcriptionally active NICD. In keeping with the hypothesized heightened 
transcriptional activity of the mutant NICD, Mec-1/KONICD-M clones showed the highest 
expression levels of both target genes (Fig. 1C-D).  
These results indicate that these cell variants represent suitable models to study the 
role of NOTCH1 and the impact of PEST domain mutations on CLL. 
RNA sequencing highlights down-modulation of genes involved in intracellular 
signaling and chemotaxis in Mec-1/KO cells 
Two genetically distinct Mec-1/WT and Mec-1/KO clones were analyzed for gene 
expression by RNA sequencing. Cells were examined under standard culture conditions 
to highlight gene expression differences occurring at baseline. A total of 1,332 genes 
were differentially expressed; in KO cells, 803 genes were down-regulated and 529 up-
regulated (Fig. 2A). NOTCH1, along with genes belonging to the gene ontology (GO) 
category “NOTCH1 signaling” was down-regulated in the KO cells (Fig. 2B), indirectly 
validating the model. In-depth analysis of the genetic pathways indicated that 
“intracellular signaling”, “chemotaxis”, “immune response”, and “cell proliferation” 
were the most frequently down-modulated on NOTCH1 loss (Fig. 2C-D). On the other 
hand, genes in the categories “MAPK regulation,” “response to stress,” and “apoptosis” 
were present in the two-fold up-modulation list (Fig. 2C-D). 
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Mec-1/KO cells show impaired growth and chemotaxis due to decreased MAPK 
signaling and STAT3 activation 
In keeping with the RNAseq results, Mec-1/KO cells were characterized by diminished 
growth under conventional culture conditions and reduced survival upon serum 
deprivation. (Fig. 3A-B). Furthermore, Mec-1/KO cells showed significantly decreased 
chemotactic responses toward CCL19, a chemokine that drives CLL localization to the 
lymph nodes (21-23) (Fig. 3C). Both phenotypic behaviors were rescued by re-expression 
of the NICD and were further enhanced in cells expressing the NICD-M. In particular, 
KONICD-M clones grew more than KONICD clones, as determined by MTT assays. KONICD-M 
clones also showed enhanced chemotaxis towards CCL19, in keeping with the 
hypothesis that the PEST domain mutation confers functional advantages (Fig. 3A-C).  
One possible explanation of the impaired chemotaxis of Mec-1/KO is reduced 
expression of CCR7, the CCL19 receptor, as highlighted by RNAseq data (Fig. 2D).  
Analysis by qRT-PCR (Fig. 3D) confirmed that CCR7 levels were significantly lower in 
Mec-1/KO than in Mec-1/WT cells, as confirmed also at the protein level (fig S3A). 
Unlike WT cells, Mec-1/KO cells did not respond to CCL19 exposure with increased actin 
polymerization and cytoplasmic Ca2+ mobilization (fig. S3B-D). Furthermore, analysis of 
signal transduction indicated significantly reduced levels of MAPK tyrosine 
phosphorylation, both before and after the addition of CCL19. Reduced activation was 
evident when studying JNK, p38 and, to a lesser extent, ERK1/2, suggesting that MAPK 
signaling is globally disturbed in Mec-1/KO cells (Fig. 3E).  
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Reconstitution of these cells with NICD or NICD-M constructs restored CCR7 expression 
(Fig. 3D), which was higher in the presence of the NICD-M. Reconstituted cells also 
exhibited restored actin polymerization (fig. S3C) and signal transduction, as indicated 
by tyrosine phosphorylation of JNK, p38, and, to a lesser extent, ERK1/2, both in 
unstimulated cells and in cells exposed to CCL19. This effect was more pronounced in 
KONICD-M cells; specifically, the intensity (in the case of JNK phosphorylation) and 
duration (in the case of p38 and ERK1/2 phosphorylation) of the signal were enhanced 
in KONICD-M cells relatively to the WT counterpart. Functionally, Mec-1/KONICD cells 
almost completely regained the ability to migrate in response to CCL19, with Mec-
1/KONICD-M cells exhibiting the highest migration levels (Fig. 3C). 
STAT3 is a transcription factor activated by MAPKs and directly regulating CCR7 gene 
expression (24). As expected from the loss of CCR7 expression, Mec-1/KO cells  showed 
severely compromised phosphorylation of STAT3, both before and after stimulation 
with CCL19, compared to the WT. This activity was restored in Mec-1/KONICD and even 
more in Mec-1/KONICD-M (Fig. 3E). This observation suggests that failed STAT3-dependent 
gene transcription results in reduced expression of the chemokine receptor, which in 
turn decreases cellular chemotaxis towards CCL19. 
Mec-1/KO cells are characterized by an over-expression of the tumor suppressor gene 
DUSP22 
The RNAseq data indicated that Mec-1/KO cells expressed genes involved in negative 
regulation of MAPK signaling at a significantly higher levels than control cells. Seven 
genes were listed in this category, namely PRKCA, LAX1, SPRED1, SPRED2, DUSP22, 
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PDCD4 and TP73 (Fig. 4A). Of these, the tumor suppressor gene DUSP22 was the most 
differentially expressed between Mec-1/WT and Mec-1/KO cells (Figs. 4B and S4). 
Expression of this gene dropped in Mec-1/KONICD and – more significantly – in Mec-
1/KONICD-M (Fig. 4B), indicating that transcriptionally active NOTCH1 impairs its 
expression. These differences were maintained at the protein level, as shown by WB 
(Fig. 4C).  
DUSP22 codes for a protein phosphatase that inactivates MAPK and STAT3 (25, 26), 
providing a mechanistic explanation for the failed phosphorylation of STAT3 and 
decreased CCR7 expression. These findings led to the working hypothesis that DUSP22 
overexpression leads to both direct and, via MAPK, indirect STAT3 inhibition, failed CCR7 
transcription, and, ultimately, decreased chemotaxis to CCL19. 
To confirm this hypothesis, Mec-1/WT cells were transiently transfected with a DUSP22-
GFP construct (Fig. 4D). Overexpression of the molecule at 24 hours was shown by WB 
and confirmed by flow cytometry (FC) (Fig. 4E and not shown).  In line with the working 
hypothesis, Mec-1/WT cells overexpressing DUSP22 were characterized by decreased 
STAT3 activation, CCR7 expression, and chemotaxis toward CCL19 (Fig. 4E-F-G). 
Conversely, silencing of DUSP22 expression in MEC-1/KO cells, as obtained by 
transfection with a specific siRNA (Fig. 4H), was followed by increased STAT3 
phosphorylation, CCR7 expression, and chemotaxis to CCL19 (Fig. 4I- K). 
The NICD modulates nuclear circuits involving HDAC1 and DMT3A 
To explain how NOTCH1 and PEST domain mutations could affect DUSP22 expression, 
we hypothesized a role of promoter methylation of the gene, consistent with 
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observations from other models (27). Therefore, a methylation-specific PCR was 
performed to investigate the methylation status of the DUSP22 promoter. We found 
that KO clones displayed a DUSP22 promoter that was significantly less methylated than 
its WT counterpart (Figs. 5A and S5A). When the NICD was reintroduced into Mec-1/KO 
cells, methylation of the DUSP22 promoter increased, while gene expression decreased, 
suggesting a NOTCH1-dependent mechanism. Expression of the NICD-M construct 
showed a further and significant increase in promoter methylation (Fig. 5A). Treatment 
of Mec-1/WT cells with 5’-2-deoxy-azacytidine (5-AZA), which inhibits the activity of 
DNMT3A (28), was followed by decreased DUSP22 promoter methylation (Fig. 5B), and 
subsequent significant increase in DUSP22 mRNA levels (Fig. 5C). As expected, treated 
cells showed significantly decreased expression of CCR7 (Fig. 5D), greatly impaired 
MAPK signaling, and STAT3 phosphorylation both before and after CCL19 stimulation 
(Fig. 5F) and a resultant marked decrease in CCL19-driven chemotaxis (Fig. 5E). 
These findings suggest that expression of the NICD alters methylation activity of 
DNMT3A. Previous evidence indicates that NOTCH1 contributes to epigenetic regulation 
of gene expression through the displacement of HDACs from the RBPJk complex (20). 
Furthermore, it is known that HDAC1 can bind to and stabilize DNMT3A, thus promoting 
gene methylation (29, 30). Therefore, we hypothesized that the presence of the NICD, 
by competing with and displacing HDAC1 from its interaction with RBPJk, would 
promote the formation of a HDAC1/DNMT3A complex, resulting in increased 
methylation of the DUSP22 promoter. 
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The presence of HDAC1-DNMT3A complexes was evaluated by IP assay in nuclear 
lysates of Mec-1/WT, Mec-1/KO, KONICD and KONICD-M. Mec-1/KO cells showed 
significantly lower levels of HDAC1 bound to DNMT3A, compared to the Mec-1/WT 
counterparts. However, the association was restored in Mec-1/KONICD and Mec-1/KONICD-
M cells. In these immunoprecipitates HDAC1 was mainly found in a homodimeric form of 
120 kD, which is reportedly enzymatically active (31)  (Fig. 5G).  
Finally, chromatin immunoprecipitation experiments confirmed that DNMT3A was 
bound to the DUSP22 promoter in Mec-1/WT, KONICD, and KONICD-M, while little or no 
DNMT3A binding was observed in Mec-1/KO cells (Fig. 5H). 
CLL patients with a NOTCH1-mutated clone are characterized by lower levels of 
DUSP22, increased methylation of the DUSP22 promoter, and increased chemotaxis to 
CCL19 
We then performed a retrospective analysis on a cohort of 113 patients with confirmed 
CLL diagnoses (Table S1). We first divided patients on the basis of the NOTCH1 
mutational burden, determined using a quantitative ARMS-PCR approach adapted with 
a SYBR-green-based method (Fig. 6A).  
Using RNA samples available for 90 patients, we determined DUSP22 mRNA levels in 
purified CLL cells by qRT-PCR. In agreement with previous data (32), patients showing 
molecular (absence of somatic mutations in the IgHV genes) or clinical (disease stage, 
therapy requirement) characteristics of aggressive disease displayed significantly lower 
DUSP22 levels (fig. S6A-C). Furthermore, in this cohort, DUSP22 expression was inversely 
correlated to the percentage of NOTCH1-mutated alleles (Fig. 6B). By applying a 
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previously defined cut-off for variant allele frequency (VAF) of 12% (33), patients were 
divided into two groups, with those <12% considered subclonal. According to this 
classification, 56 patients harbored clonal NOTCH1 mutations, while the remaining 34 
patients were in the subclonal range. Significantly lower DUSP22 levels characterized 
patients with a clonal NOTCH1 mutation as compared to patients with subclonal 
mutations (Fig. 6C). This finding was confirmed at the protein level in a small subgroup 
of patients, by determining DUSP22 expression in whole cell lysates (Fig. 6F). By 
monitoring DUSP22 mRNA levels in sequential samples collected from five patients, we 
observed a decrease in expression as the NOTCH1-mutated clone expanded and vice-
versa (Figs. 6D and S6D). 
In concordance with observations of the cell line model, differences in DUSP22 
expression were due to different levels of methylation of the DUSP22 promoter:  clinical 
samples showing low levels of DUSP22 mRNA were characterized by higher methylation 
of the promoter (Fig. 6E). In addition, patients with low DUSP22 mRNA levels were 
characterized by a more marked constitutive STAT3 phosphorylation (Fig. 6F), higher 
CCR7 mRNA expression levels (Fig. 6G), and, ultimately, enhanced chemotaxis towards 
CCL19 (Fig. 6H). 
Generation of a Mec-1 variant carrying truncating mutations on NOTCH1 PEST domain 
The data obtained indicate that NOTCH1 signaling regulates nuclear circuits, which in 
turn affect the expression of genes involved in growth and in chemotaxis towards 
CCL19. This suggests that the cells’ ability to reach peripheral lymphoid organs, where 
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the antigen and co-stimulatory signals are available, may differ according to NOTCH1 
mutational status.  
To study the impact of NOTCH1 PEST domain mutations in vivo, we again exploited 
CRISPR/Cas9 technology to generate a Mec-1 variant with PEST domain mutations (fig. 
S1A). To this end, Mec-1 cells were transiently transfected with a Cas9-GFP construct 
and an RNA guide driving the enzyme to cut NOTCH1 exon 34 in position 7478 
(Reference sequence: NM_017617.3). GFP+ cells were sorted, cloned by serial dilutions, 
and analyzed by Sanger sequencing to identify missense mutations originated by the 
NHEJ-mediated DNA repair. The mutations truncate NOTCH1 PEST domain, mirroring 
the  ∆CT_7541-7542 mutation that has been described in CLL patients and is carried by 
Mec-1/KONICD-M cells. Three clones with different frameshift insertion/deletions up to 8 
nucleotides (indicated as Mec-1/PEST, P2493*fs) were established (fig. S7A). Similar to 
primary CLL cells, these clones were heterozygous, expressing both the WT and the 
mutant alleles, as documented by WB (fig. S7B). 
As expected, under steady-state conditions in vitro these cells did not show significant 
differences from WT cells in terms of constitutive NOTCH1 pathway activation (fig. S7D-
E). They consistently required engagement by the ligand to initiate signaling (15). This 
conclusion was reached after the NICD band appeared upon co-culture of Mec-1/WT or 
Mec-1/PEST cells with human bone marrow stromal cells (HS-5) that had been 
transduced with a lentiviral vector to overexpress either Jagged1 or DLL1 (Figs. 7A and 
S8). In these conditions, the NICD-PEST was more stable than the NICD-WT, as shown by 
monitoring protein stability following leukemia-stroma co-cultures. Results indicate that 
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the NICD-WT disappeared rapidly once leukemic cells were separated from the ligand-
expressing stroma, as predicted in physiological conditions. In contrast, the NICD-PEST 
remained visible by WB up to 24 hours after ending the co-cultures (Fig. 7B-C). In line 
with this observation, expression of the NOTCH1 target gene HES1 in Mec-1/PEST cells 
was significantly higher than in Mec-1/WT cells up to eight hours after ending the co-
culture (Fig. 7D). Interestingly, activation of NOTCH1 signaling induced by HS-5 
correlated with a significant decrease of DUSP22 expression, compared to cells cultured 
alone (Fig. 7E). The effect was more pronounced in Mec-1/PEST cells (Fig. 7E), in which 
DUSP22 levels remained significantly down-modulated up to 24 hours after ending the 
co-culture (fig. S7F). In line with the working hypothesis, CCR7 levels were increased 
upon co-culture on HS-5, with the strongest effect in the PEST clones (Fig. 7F). 
These results suggest that Mec-1/PEST cells, while less serviceable for functional studies 
in vitro, can be effectively exploited in xenograft models, due to the documented cross-
reactivity between human and mouse NOTCH1 ligands (34). When tested, a prominent 
band corresponding to the WT or mutant NICD was in fact observed after recovering 
Mec-1/WT or /PEST from immunocompromised mice (fig. S7G). 
Mec-1/WT, Mec-1/KO and Mec-1/PEST show different spreading in xenograft models 
We compared engraftment and spreading of Mec-1/WT, /KO, and /PEST clones in 
NOD/SCID/γ-chain-/- (NSG) mice. Mice were injected intravenously (i.v.) with at least two 
different clones for each of the Mec-1 lines. Subsequent engraftment was monitored by 
magnetic resonance imaging (MRI) performed two and three weeks post-injection. 
While all cell lines showed 100% engraftment, colonization was markedly different. 
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Mec-1/KO cells localized to the kidney but showed limited diffusion to other 
parenchymatous and non-parenchymatous organs in the following weeks (Fig. 8A). In 
contrast, mice xenografted with Mec-1/WT cells showed both renal disease and nodal 
metastases to the liver (Fig. 8A). Microscopically, FC analysis for CD19 and CD20 
approximately four weeks after engraftment also demonstrated human leukemic cells in 
the spleen and in the brain. Animals engrafted with Mec-1/PEST cells were 
characterized by the least kidney involvement (Fig. 8A-C), by liver disease comparable to 
the Mec-1/WT mice (fig. S9A-B), and by markedly greater involvement of the spleen and 
the brain. This was documented both macroscopically, as the spleens obtained by Mec-
1/PEST were significantly heavier than those of the two other animal groups (Fig. 8B), 
and microscopically, by leukemic cell count or immunohistochemical analysis (Fig. 8C-G). 
In accordance with in vitro results, DUSP22 mRNA levels were markedly decreased both 
in Mec-1/WT and/PEST cells recovered after in vivo growth (fig. S9D). These results 
suggest that Mec-1/PEST cells have a unique tropism towards the spleen and brain, two 
organs in which an active role for CCL19 has been identified (35, 36).  
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Discussion 
After the systematic application of next-generation sequencing technologies to the 
analysis of cancer cells, scientists have assembled an incredible wealth of novel data on 
the genomic architecture of tumors. However, the functional role of these mutations in 
the development and progression of diseases such as CLL remain to be fully 
elucidated(37). NOTCH1 mutations were among the first to be identified using whole 
exome sequencing, and their prevalence and prognostic power for CLL patients has 
since been extensively studied (6). To address the question of the role of NOTCH1 in CLL 
biology and identify the effects of its most commonly represented mutation, we 
exploited the CRISPR/Cas9 technology to re-create NOTCH1 mutations typical of CLL 
patients in a cell line model. Based on patient analysis, computer predictions, and 
previous studies (16), these mutations would appear to have a milder phenotypic 
impact, far from the strong and driving effect of NOTCH1 mutations in acute leukemia. 
The first approach was to compare the transcriptome of cells expressing a WT NOTCH1 
to that of cells lacking the gene, to highlight the NOTCH1-regulated pathways. We then 
reconstituted Mec-1/KO cells with a WT or M NICD and studied their behavior. Using 
this approach, growth and chemotaxis were the two pathways most impacted by 
NOTCH1 loss. Consistently, Mec-1/KO cells grew less rapidly and migrated less towards 
CCL19 than their WT or reconstituted counterparts. Importantly, in all biologic assays 
clones reconstituted with a NICD-M construct performed slightly but significantly better 
than clones reconstituted with a NICD-WT, in line with the predicted mild effect of the 
mutation. The model that we propose to explain these observations is based on a 
 17 
nuclear ecosystem composed of four molecular actors: NICD, RBPJk, HDAC1, and 
DNMT3A. These four molecules interact as follows: NICD needs RBPJk to form a 
functional transcriptional complex; however, in the absence of NICD, RBPJk is bound to 
HDAC1 in a repressor complex. In turn, HDAC1 can bind and stabilize DNMT3A, 
promoting its activity (fig. S10). It is a reasonable presumption that even a slight 
modification in the stability of the NICD can perturb these interactions, ultimately 
modulating DNMT3A activity.  
In the CLL model analyzed, DUSP22 is a key target molecule of DNMT3A activity. Hence, 
bioavailability of the NICD directly affects methylation levels in the DUSP22 promoter, 
ultimately regulating its expression. Confirmation of this hypothesis was obtained by 
showing that the DUSP22 promoter was hypomethylated in Mec-1/KO and 
hypermethylated in KONICD and KONICD-M cells. Expression of the molecule were 
consistently highest in Mec-1/KO cells and lowest in KONICD-M cells.  
DUSP22 is a member of the dual-specific phosphatase family. It modulates activity of 
MAPK family members, including JNK (both activated and inactivated) and p38 
(inactivated), and it inactivates STAT3 (25, 26, 38). Recent studies in colon cancer cells 
have revealed that this molecule may act as a tumor suppressor, as its loss is associated 
with increased migration and motility, as well as an inferior outcome (39). In CLL cells, 
DUSP22 is overexpressed, correlating with the presence of somatic mutation in the IgHV 
genes (32), in the subset of patients with good prognosis.   
As expected with an increased expression of DUSP22, Mec-1/KO showed constitutively 
decreased STAT3 phosphorylation, which in turn is a transcriptional regulator of CCR7, 
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the CCL19 receptor. Consequently, Mec-1/KO clones showed the lowest CCR7 
expression and the lowest chemotactic responses to CCL19. On the contrary, Mec-
1/KONICD-M showed the highest levels of baseline STAT3 phosphorylation, with the 
highest levels of CCR7 expression and subsequent CCL19-driven chemotaxis. Silencing of 
DUSP22 in Mec-1/KO and overexpression in Mec-1/WT confirmed that STAT3 
phosphorylation, CCR7 expression, and chemotaxis are directly impacted by modulation 
of DUSP22 levels. 
These observations were confirmed in a large cohort of primary cases. By comparing 
primary CLL cells carrying NOTCH1 mutations at the clonal and subclonal levels, we 
observed significantly hypermethylation of DUSP22 with lower mRNA and protein levels 
in clonal compared with subclonal patients. The clonal subset consistently showed 
constitutive STAT3 phosphorylation, expressed higher levels of CCR7, and migrated 
more efficiently to CCL19 than the subclonal subset. 
We then used CRISPR/Cas9 technology to generate cells with  a mutation pattern similar 
to that observed in patients. Several clones with a shorter PEST domain were generated 
and studied. Our study shows that cells carrying a WT or a PEST domain mutant NOTCH1 
must still interact with the ligand to activate NOTCH1 pathway. By following the 
signaling pathway over time, we confirmed that, at the molecular level, PEST domain 
mutations increase the stability of the NICD and maintain the activation of NOTCH1 
signaling for longer, when compared to the WT. Moreover, ligand-mediated NOTCH1 
activation resulted in a further decrease of DUSP22 levels, confirming NOTCH1-
dependent modulation.  
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Even if this model has intrinsic limitations for in vitro studies, it may be used in vivo, 
where mouse Jagged and DLL family molecules are reported to bind and activate human 
NOTCH1 (16, 34). Xenograft studies showed that Mec-1/PEST clones were characterized 
by markedly increased metastatic properties, with extensive colonization of the liver, 
the spleen, and the brain, in contrast to the Mec-1/KO cells, which remained 
predominantly localized in the kidney, the first engrafted organ (40).  
Intriguingly, CCR7 has been previously recognized as an entry signal to the brain for 
leukemic cells, and activating mutations of NOTCH1 have been found to increase CCR7 
expression (35). CLL localization to the brain is infrequent; however, there are reports of 
central nervous system infiltration occurring with RS. As NOTCH1 mutations have been 
proposed as a risk factor for RS, future studies are needed to understand if this patient 
subset may have a higher risk of CNS localization of the disease. 
Considered together, these results show that PEST domain mutations increase the 
stability of the NICD and the expression of NOTCH1 target genes, in turn affecting a 
complex nuclear balance. The final outcome for the CLL cell is decreased expression of 
the tumor suppressor gene DUSP22, with modification in the migratory properties of 
the leukemic cell. As CCL19 regulates homing to secondary organs, one could speculate 
that NOTCH1 mutations may favor CLL recirculation to lymph nodes and spleen, where 
the local environment favors proliferation and protection from apoptosis, two 
conditions that are associated with a more aggressive disease process and an 




The aim of the study was to highlight NOTCH1-dependent mechanisms contributing to 
CLL pathogenesis and progression, as well as the advantages that PEST domain 
truncating mutations confer to leukemic cells. Mec-1, an accepted NOTCH1-WT CLL-like 
model was exploited to generate a working model, overcoming the intrinsic limits of 
primary CLL cells that have so far restrained a mechanistic characterization of NOTCH1 
functional role. Two parallel but integrated strategies were adopted, both based on the 
CRISPR/Cas9 system. First, we generated a NOTCH1-KO Mec-1 model to identify 
NOTCH1-regulated cellular processes, by comparing the transcriptome profile of the KO 
and WT cells. Expression of the NICD-WT or NICD-PEST was restored in KO cells by 
lentiviral infection. These models were used to rescue the KO phenotype and to study 
the behavior of the mutant. The findings were then confirmed on samples from CLL 
patients, obtained after informed consent, in accordance with Institutional Guidelines 
and the Declaration of Helsinki.  
Second, we directed Cas9 on exon34 of NOTCH1 to truncate the PEST domain, 
recreating the mutation seen in CLL patients. This second approach was pursued to 
characterize the behavior of PEST-mutated cells in vivo where leukemic cells are known 
to find the ligand, which is necessary to generate the NICD and to activate signaling. In 
vivo studies were performed according to Institutional Guidelines and with the approval 




Detailed descriptions of experimental methods are provided in Supplementary Materials 
and Methods. 
Statistical Analyses 
Statistical analyses were performed with GraphPad v6 (GraphPad Software Inc, La Jolla, 
CA, USA) and are presented as box plots or scatter plots. In the text, data are presented 
as mean±SD. Mann-Whitney or Wilcoxon matched-pairs signed rank test were used to 
determine statistical significance. In the case of grouped analyses (time- and variant-
dependent results), statistics were performed with the 2-way ANOVA test. P<0.05 (*); 
P<0.01 (**); P <0.001 (***); P >0.0001 (****).  
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Supplementary Materials 
Materials and Methods 
Fig. S1. Schematic view of the working model generated by CRISPR/Cas9. 
Fig. S2. IP of NOTCH1 in Mec-1/KO, KONICD and KONICD-M. 
Fig. S3. Calcium fluxes and Actin polymerization in response to CCL19 
Fig. S4. qRT-PCR of other genes encoding negative regulators of MAPK. 
Fig. S5. Example of MS-PCR image and control experiments validating the nuclear 
complex 
Fig. S6. Analysis of DUSP22 levels in CLL samples divided according to clinical and 
molecular features 
Fig. S7. Validation of Mec-1/PEST cells 
Fig. S8. FC analysis of ligand expression in HS-5 cells 
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Fig. 1. Generation of a cell line model based on Mec-1 CLL-like cells. (A) WB analysis of 
NOTCH1 expression in the Mec-1 variants. Lane #1 and 2: Mec-1/WT; Lane #3 and 4: 
Mec-1/KO; Lane #5 and 6: Mec-1/KONICD; Lane #7 and 8: Mec-1/KONICD-M. Actin was used 
as loading control. (B) qRT-PCR analysis of NOTCH1 levels in Mec-1 variants. qRT-PCR 
analysis of HES1 (C) and DTX1 (D) expression in Mec-1 variants.  
Fig. 2. Mec-1/WT and /KO cells differentially express genes involved in the regulation 
of proliferation and chemotaxis. (A) Venn diagram summarizing the differentially 
expressed genes in Mec-1/WT and KO cells. (B) Heatmap of the “NOTCH1 signaling” GO. 
(C) Cumulative graph showing the GO clusters more significantly (Log10 p-value) up- or 
down-modulated in the Mec-1/WT and KO cells. (D) Heatmaps and gene lists of the 
differentially modulated GO clusters “chemotaxis”, “proliferation”, “MAPK regulation” 
and “apoptosis”. Two independent clones were analyzed, indicated by #1 and #2. 
Fig. 3. NOTCH1 expression impacts on the proliferation and the migratory potential of 
leukemic cells. (A) Absorbance values of MTT assays (arbitrary units, a.u.). Values are 
represented on a log2 scale. (B) Viability curve of Mec-1 variants cultured for the 
indicated time points under stressed culture condition (RPMI 1%FCS). Apoptosis was 
measured and the percentage of Annexin V-/PI- population was monitored and plotted. 
Statistically significant differences at 72h were: WT vs. KO P=0.0001; KO vs. KONICD 
P=0.001; KO vs. KONICD-M P=0.001. (C) Chemotaxis vs. CCL19. Dashed line indicates 
spontaneous cell migration in the absence of CCL19. (D) qRT-PCR analysis of CCR7 levels 
in Mec-1 variants. Values are represented in a log2 scale. (E) WB analysis of MAPK 
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activation in response to CCL19 stimulation. Phosphorylation on JNK, p38, ERK1/2, and 
STAT3 was evaluated in the different Mec-1 variants at basal conditions (-) and after 
stimulation with CCL19 (+) for the indicated time points. Levels of non-phosphorylated 
JNK, p38, ERK1/2, and STAT3 are shown as controls. 
Fig. 4. Expression of DUSP22 modulates the chemotactic response to CCL19. (A) 
Heatmap of the genes annotated in the GO “Negative regulators of MAPK” showing 
increased expression in the KO cells. (B) qRT-PCR analysis of DUSP22 expression in Mec-
1 variants. Values are represented on a linear scale. (C) WB analysis of DUSP22 
(indicated by the arrow) in Mec-1 variants. (D) qRT-PCR analysis of DUSP22 levels in 
transiently transfected Mec-1/WT. (E) WB analysis of DUSP22 expression (TR, 
transfected; E, endogenous) and STAT3 phosphorylation in Mec-1/ WT cells transiently 
transfected with GFP alone or with a DUSP22-GFP plasmid. Transfected DUSP22 is found 
at a different molecular weight from the endogenous one because of a GFP-tag. Levels 
of non-phosphorylated STAT3 are shown as control. (F) qRT-PCR analysis of CCR7 
expression in transiently transfected Mec-1/WT. (G) Chemotaxis vs. CCL19, in GFP- and 
DUSP22- transfected Mec-1/WT. (H) qRT-PCR analysis of DUSP22 levels in Mec-1/KO 
cells transiently transfected with a scrambled (Scr) siRNA or a DUSP22-targeting siRNA. 
(I) WB analysis of DUSP22 expression and STAT3 phosphorylation in Mec-1/ KO cells 
transiently transfected with Scr siRNA  or with a DUSP22-siRNA. Levels of non-
phosphorylated STAT3 are shown as controls. (J) qRT-PCR analysis of CCR7 expression in 
transiently transfected Mec-1/KO. (K) Chemotaxis vs. CCL19 in Scr- and siRNA DUSP22- 
transfected Mec-1/KO.  
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Fig. 5. Differential expression of DUSP22 is due to a different methylation pattern as a 
consequence of NICD-modulated nuclear complexes. (A) MS-PCR of Mec-1 variants. 
Results are represented in a log2 scale. (B) MS-PCR of Mec-1/WT treated with 5-AZA or 
DMSO. (C) qRT-PCR analysis of DUSP22 levels in Mec-1/WT treated with 5-AZA or 
DMSO. Values are represented on a log2 scale. (D) qRT-PCR analysis of CCR7 expression 
in Mec-1/WT treated with 5-AZA or DMSO. (E) Chemotaxis vs. CCL19 in Mec-1/WT 
treated with 10µM 5-AZA or DMSO. Results are represented on a log2 scale. (F) WB 
analysis of MAPK activation in response to CCL19 stimulation in Mec-1/WT treated with 
5-AZA or DMSO. Phosphorylation on JNK, p38, ERK1/2, and STAT3 was evaluated at 
basal conditions (-) and after stimulation with CCL19 (+) for the indicated time points. 
Levels of non-phosphorylated JNK, p38, ERK1/2, and STAT3 are shown as control. (G) 
Identification of a nuclear complex containing HDAC1 and DNMT3A. DNMT3A was 
immunoprecipitated in nuclear cell lysates of Mec-1 variants, and the membrane was 
blotted with an anti-HDAC1 antibody (top) or an anti-DNMT3A antibody as internal 
control (bottom). A non-IP nuclear cell lysate (ncl) was used as positive control. (H) ChIP 
assay performed by IP of DNMT3A or IgG in the nuclear lysates of Mec-1 variants and 
amplification of DUSP22 promoter. 
Fig. 6. CLL samples with clonal NOTCH1 mutation down-modulate DUSP22 and have an 
increased migratory potential. (A) Distribution of the VAF in our cohort of NOTCH1-M 
CLL samples (n=113). (B) Pearson inverse correlation between NOTCH1-VAF and DUSP22 
levels. (C) qRT-PCR of DUSP22 levels in CLL patients divided into subclonal (VAF≤ 12%, 
n=34) and clonal (VAF>12%, n=56) NOTCH1-M samples. Values are represented on a Log 
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scale. (D) Analysis of DUSP22 expression and NOTCH1 VAF in the follow-up of 3 CLL 
patients. DNA and RNA CLL samples collected at the same time were analyzed by ARMS-
SYBR-PCR and qRT-PCR, respectively. (E) MS-PCR of NOTCH1-M CLL samples divided 
according to DUSP22 expression. Results are represented on a log2 scale. (F) WB of 
DUSP22 expression and STAT3 phosphorylation in NOTCH1-M CLL samples divided 
according to DUSP22 levels. Levels of non-phosphorylated STAT3 are shown as controls. 
(G) qRT-PCR of CCR7 expression in NOTCH1-M CLL samples divided according to DUSP22 
levels. Values are represented in a log2 scale. (H) Migration vs. CCL19 of NOTCH1-M CLL 
cells divided according to DUSP22 levels. Values are represented in a log2 scale. 
Fig. 7. Mec-1/PEST cells harbor truncating mutations in NOTCH1 PEST domain and 
show sustained signaling upon ligand binding. (A) WB analysis of NOTCH1 cleavage 
after co-culture on HS-5/JAG1 or /DLL1. Mec-1/WT and PEST were lysed in basal 
condition (-) or after 20 hours co-culture. Co-culture on mock GFP HS-5 was used as a 
control. Two independent PEST clones are shown. Arrows indicate WT or mutated NICD 
band. (B) WB showing the kinetic of NICD degradation after ligand withdrawal. Cells 
were co-cultured on HS5/DLL1 as in panel (A) and immediately lysed (0h) or removed 
from the HS-5 layer and lysed at the indicated time points (3, 8, 24 hours post 
activation). Quantification of NICD band intensity over actin band intensity is reported in 
(C). Statistics were performed with the 2-way ANOVA test. (D) qRT-PCR of HES1 
expression upon NOTCH1 activation by ligand-expressing HS-5 and after ligand 
withdrawal. RNA was extracted at the indicated time points, HES1 levels measured by 
qRT-PCR and expressed as fold change over basal levels. Statistics was performed with 
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the 2-way ANOVA test. (E) qRT-PCR analysis of DUSP22 expression in Mec-1/WT and 
PEST at basal levels (-) or after co-culture on HS-5/DLL1 (+).(F) qRT-PCR analysis of CCR7 
expression in Mec-1/WT and PEST at basal levels (-) or after co-culture on HS-5/DLL1 (+).  
Fig. 8. Mec-1 variants show  different spreading in vivo. (A) MRI images of mice 
injected with Mec-1/WT, /KO and /PEST 3 weeks after injection. The liver and the 
kidneys are shown in coronal sections, and the spleen is shown in axial section. 
Metastatic nodules and spleens are indicated by the arrows: S, superior; I, inferior; R, 
right; L, left; A, anterior; P, posterior. (B) Kidneys’ (top) and spleen’s (bottom) weight in 
mice injected with Mec-1 variants. Pictures of the spleens are also shown. (C) FC analysis 
of Mec-1 cells (CD19+/CD20+) in the liver, spleen and brain (from left to right). (D) IHC of 
CD20+ areas in the spleen of mice injected with Mec-1 variants. Magnification 4X. The 
graph in (E) represents the quantification of CD20+ areas. (F) IHC of CD20+ areas in the 
brain of mice injected with Mec-1 variants. Magnification 2.5X and 4X. The graph in (G) 
represents the quantification of CD20+ areas.   
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